Recombinant vaccines for hepatitis E.

Abstract

Hepatitis E virus causes epidemics of acute hepatitis in many developing countries. It infrequently causes disease in developed countries, but avirulent strains might circulate. Some evidence suggests that hepatitis E might be a zoonosis. There is probably only a single serotype. A candidate vaccine consisting of baculovirus-expressed recombinant capsid protein protected macaques from hepatitis E--it passed phase I clinical trials and is currently scheduled for phase II/III clinical trials.

• Authors: S U Emerson, R H Purcell
• Journal: Trends in molecular medicine (Trends Mol Med) Vol. 7 Issue 10 Pg. 462-6 (Oct 2001) ISSN: 1471-4914 [Print] England
• PMID: 11597521 (Publication Type: Journal Article, Review)

Chemical References

• ORF2 protein, Hepatitis E virus
• Recombinant Proteins
• Vaccines, Synthetic
• Viral Hepatitis Vaccines
• Viral Proteins

Topics

• Animals
• Clinical Trials as Topic
• Disease Models, Animal
• Hepatitis E (immunology, prevention & control)
• Hepatitis E virus (genetics, immunology, physiology)
• Humans
• Immunotherapy, Active (methods, trends)
• Recombinant Proteins (immunology)
• Vaccines, Synthetic (genetics, immunology)
• Viral Hepatitis Vaccines (genetics, immunology)
• Viral Proteins (genetics, immunology)